University of Texas Southwestern Medical Center, Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, 7232 Greenville Avenue, Dallas, TX 75231, USA; Kyushu University, School of Medicine, Department of Medicine and Biosystemic Science, Division of Cardiology, 3-1-1 Maidashi Higashi-ku Fukuoka City, Clinical Research Building B6F Fukuoka, Zip:812-8582, Japan.
Heart Fail Clin. 2020 Jul;16(3):271-282. doi: 10.1016/j.hfc.2020.02.005.
Noninvasive positive pressure ventilation (NIPPV), which can be applied without endotracheal airway or tracheostomy, has been used as the first-line device for patients with acute decompensated heart failure (ADHF) and cardiogenic pulmonary edema. Positive airway pressure (PAP) devices include continuous PAP, bilevel PAP, and adaptive servoventilation. NIPPV can provide favorable physiologic benefits, including improving oxygenation, respiratory mechanics, and pulmonary and systemic hemodynamics. It can also reduce the intubation rate and improve clinical symptoms, resulting in good quality of life and mortality.
无创正压通气（NIPPV），无需经气管内气道或气管切开即可应用，已被用作急性失代偿性心力衰竭（ADHF）和心源性肺水肿患者的一线设备。正压通气（PAP）设备包括持续 PAP、双水平 PAP 和适应性伺服通气。NIPPV 可提供有利的生理益处，包括改善氧合、呼吸力学以及肺和全身血液动力学。它还可以降低插管率并改善临床症状，从而提高生活质量和降低死亡率。
